These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
112 related articles for article (PubMed ID: 30095329)
41. Targeting Long Noncoding RNA with Antisense Oligonucleotide Technology as Cancer Therapeutics. Zhou T; Kim Y; MacLeod AR Methods Mol Biol; 2016; 1402():199-213. PubMed ID: 26721493 [TBL] [Abstract][Full Text] [Related]
42. Long noncoding RNA MALAT1 regulates endothelial cell function and vessel growth. Michalik KM; You X; Manavski Y; Doddaballapur A; Zörnig M; Braun T; John D; Ponomareva Y; Chen W; Uchida S; Boon RA; Dimmeler S Circ Res; 2014 Apr; 114(9):1389-97. PubMed ID: 24602777 [TBL] [Abstract][Full Text] [Related]
43. A cytoplasmic pathway for gapmer antisense oligonucleotide-mediated gene silencing in mammalian cells. Castanotto D; Lin M; Kowolik C; Wang L; Ren XQ; Soifer HS; Koch T; Hansen BR; Oerum H; Armstrong B; Wang Z; Bauer P; Rossi J; Stein CA Nucleic Acids Res; 2015 Oct; 43(19):9350-61. PubMed ID: 26433227 [TBL] [Abstract][Full Text] [Related]
44. Identifying Suitable Target Regions and Analyzing Off-Target Effects of Therapeutic Oligonucleotides. Pedersen L; Hagedorn PH; Koch T Methods Mol Biol; 2019; 2036():261-282. PubMed ID: 31410803 [TBL] [Abstract][Full Text] [Related]
45. Chemical Diversity of Locked Nucleic Acid-Modified Antisense Oligonucleotides Allows Optimization of Pharmaceutical Properties. Papargyri N; Pontoppidan M; Andersen MR; Koch T; Hagedorn PH Mol Ther Nucleic Acids; 2020 Mar; 19():706-717. PubMed ID: 31951854 [TBL] [Abstract][Full Text] [Related]
46. Antisense long non-coding RNA PCNA-AS1 promotes tumor growth by regulating proliferating cell nuclear antigen in hepatocellular carcinoma. Yuan SX; Tao QF; Wang J; Yang F; Liu L; Wang LL; Zhang J; Yang Y; Liu H; Wang F; Sun SH; Zhou WP Cancer Lett; 2014 Jul; 349(1):87-94. PubMed ID: 24704293 [TBL] [Abstract][Full Text] [Related]
48. Oncogenic long noncoding RNA MALAT1 and HCV-related hepatocellular carcinoma. Toraih EA; Ellawindy A; Fala SY; Al Ageeli E; Gouda NS; Fawzy MS; Hosny S Biomed Pharmacother; 2018 Jun; 102():653-669. PubMed ID: 29604585 [TBL] [Abstract][Full Text] [Related]
49. XRN2 is required for the degradation of target RNAs by RNase H1-dependent antisense oligonucleotides. Hori S; Yamamoto T; Obika S Biochem Biophys Res Commun; 2015 Aug; 464(2):506-11. PubMed ID: 26159921 [TBL] [Abstract][Full Text] [Related]
50. Strategies for In Vivo Screening and Mitigation of Hepatotoxicity Associated with Antisense Drugs. Kamola PJ; Maratou K; Wilson PA; Rush K; Mullaney T; McKevitt T; Evans P; Ridings J; Chowdhury P; Roulois A; Fairchild A; McCawley S; Cartwright K; Gooderham NJ; Gant TW; Moores K; Hughes SA; Edbrooke MR; Clark K; Parry JD Mol Ther Nucleic Acids; 2017 Sep; 8():383-394. PubMed ID: 28918038 [TBL] [Abstract][Full Text] [Related]
51. RNase H1-Dependent Antisense Oligonucleotides Are Robustly Active in Directing RNA Cleavage in Both the Cytoplasm and the Nucleus. Liang XH; Sun H; Nichols JG; Crooke ST Mol Ther; 2017 Sep; 25(9):2075-2092. PubMed ID: 28663102 [TBL] [Abstract][Full Text] [Related]
52. Differential long noncoding RNA/mRNA expression profiling and functional network analysis during osteogenic differentiation of human bone marrow mesenchymal stem cells. Zhang W; Dong R; Diao S; Du J; Fan Z; Wang F Stem Cell Res Ther; 2017 Feb; 8(1):30. PubMed ID: 28173844 [TBL] [Abstract][Full Text] [Related]
53. Global analysis of biogenesis, stability and sub-cellular localization of lncRNAs mapping to intragenic regions of the human genome. Ayupe AC; Tahira AC; Camargo L; Beckedorff FC; Verjovski-Almeida S; Reis EM RNA Biol; 2015; 12(8):877-92. PubMed ID: 26151857 [TBL] [Abstract][Full Text] [Related]
54. Long Noncoding RNA lncCAMTA1 Promotes Proliferation and Cancer Stem Cell-Like Properties of Liver Cancer by Inhibiting CAMTA1. Ding LJ; Li Y; Wang SD; Wang XS; Fang F; Wang WY; Lv P; Zhao DH; Wei F; Qi L Int J Mol Sci; 2016 Sep; 17(10):. PubMed ID: 27669232 [TBL] [Abstract][Full Text] [Related]
55. A novel integrated strategy (full length gene targeting) for mRNA accessible site tagging combined with microarray hybridization/RNase H cleavage to screen effective antisense oligonucleotides. Sun Y; Duan M; Lin R; Wang D; Li C; Bo X; Wang S Mol Vis; 2006 Nov; 12():1364-71. PubMed ID: 17149362 [TBL] [Abstract][Full Text] [Related]
56. Estimated number of off-target candidate sites for antisense oligonucleotides in human mRNA sequences. Yoshida T; Naito Y; Sasaki K; Uchida E; Sato Y; Naito M; Kawanishi T; Obika S; Inoue T Genes Cells; 2018 Jun; 23(6):448-455. PubMed ID: 29667281 [TBL] [Abstract][Full Text] [Related]
57. Antisense oligonucleotides delivered to the amniotic cavity in utero modulate gene expression in the postnatal mouse. Depreux FF; Wang L; Jiang H; Jodelka FM; Rosencrans RF; Rigo F; Lentz JJ; Brigande JV; Hastings ML Nucleic Acids Res; 2016 Nov; 44(20):9519-9529. PubMed ID: 27683224 [TBL] [Abstract][Full Text] [Related]
58. Genome-wide miRNA-profiling of aflatoxin B1-induced hepatic injury using deep sequencing. Yang W; Lian J; Feng Y; Srinivas S; Guo Z; Zhong H; Zhuang Z; Wang S Toxicol Lett; 2014 Apr; 226(2):140-9. PubMed ID: 24472605 [TBL] [Abstract][Full Text] [Related]
59. Managing the sequence-specificity of antisense oligonucleotides in drug discovery. Hagedorn PH; Hansen BR; Koch T; Lindow M Nucleic Acids Res; 2017 Mar; 45(5):2262-2282. PubMed ID: 28426096 [TBL] [Abstract][Full Text] [Related]
60. Mucin-mediated nanocarrier disassembly for triggered uptake of oligonucleotides as a delivery strategy for the potential treatment of mucosal tumours. Martirosyan A; Olesen MJ; Fenton RA; Kjems J; Howard KA Nanoscale; 2016 Jul; 8(25):12599-607. PubMed ID: 26694897 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]